Case Report: Thymoma-associated stiff person syndrome and myasthenia gravis: an index case with exploratory exome sequencing and review of reported cases - Report - MDSpire
Advertisement
Case Report: Thymoma-associated stiff person syndrome and myasthenia gravis: an index case with exploratory exome sequencing and review of reported cases
Clinical Report: Exploratory Exome Sequencing in Thymoma-Related SPS and MG
Overview
This report details a case of a 55-year-old female with thymoma-related stiff person syndrome (SPS) and myasthenia gravis (MG), highlighting the diagnostic challenges and treatment outcomes. Whole-exome sequencing revealed significant genetic mutations, contributing to the understanding of the immunopathogenic mechanisms involved.
Background
Thymoma is frequently associated with myasthenia gravis, but the coexistence of stiff person syndrome is rare, complicating diagnosis and treatment. Understanding the immunopathogenic mechanisms is crucial for effective management of these overlapping syndromes, which can significantly impact patient quality of life and treatment strategies.
The patient exhibited significant clinical symptoms including gait instability and dysphagia.
Serological testing revealed elevated levels of GAD65 and AChR antibodies.
Thymoma was confirmed via chest CT, indicating an anterior mediastinal mass.
Whole-exome sequencing identified a CACNA1A frameshift mutation and variants in immune-signaling genes.
Management with immunotherapy and thymectomy led to notable clinical improvement.
Literature review identified seven additional cases with similar findings and positive outcomes following treatment.
Clinical Implications
Clinicians should consider the potential for overlapping syndromes in patients with thymoma, particularly the association with SPS and MG. Comprehensive diagnostic evaluations, including serological and genetic testing, are essential for guiding treatment strategies and improving patient outcomes.
Conclusion
Thymoma-related SPS and MG represent a complex clinical challenge, necessitating a multidisciplinary approach to diagnosis and management. The integration of clinical, genetic, and literature findings supports a unified understanding of the underlying mechanisms.
In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent clinicians and thought leaders.